Evidence map›Paper›PMID 35616179›Full record

Observational studyJournal of diabetes investigation2022

Glycated hemoglobin level on admission associated with progression to severe disease in hospitalized patients with non-severe coronavirus disease 2019.

Ryutaro Numaguchi, Masafumi Kurajoh, Yoshikazu Hiura, Takumi Imai, Tomoaki Morioka, Mika Saito, Satoshi Shiraishi, Masanori Emoto, Yukio Nishiguchi

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ryutaro NumaguchiDepartment of Diabetes and Endocrinology, Osaka City Juso Hospital, Osaka, Japan.
Masafumi KurajohDepartment of Metabolism, Endocrinology and Molecular Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.ORCID https://orcid.org/0000-0002-2571-9375
Yoshikazu HiuraDepartment of Diabetes and Endocrinology, Osaka City Juso Hospital, Osaka, Japan.
Takumi ImaiDepartment of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Tomoaki MoriokaDepartment of Metabolism, Endocrinology and Molecular Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.ORCID https://orcid.org/0000-0002-2329-8191
Mika SaitoDepartment of Pediatrics, Osaka City Juso Hospital, Osaka, Japan.
Satoshi ShiraishiDepartment of Respiratory Medicine, Osaka City Juso Hospital, Osaka, Japan.
Masanori EmotoDepartment of Metabolism, Endocrinology and Molecular Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yukio NishiguchiDepartment of Surgery, Osaka City Juso Hospital, Osaka, Japan.
Osaka Metropolitan University · JPOsaka City General Hospital · JPOsaka City University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS/

introductionPoor glycemic control is known to be associated with severe infection development. This retrospective observational study examined whether glycemic control before coronavirus disease 2019 (COVID-19) onset contributes to progression from non-severe to severe COVID-19. MATERIALS AND

methodsGlycated hemoglobin (HbA1c) was measured on hospital admission in 415 patients with non-severe COVID-19. The outcome was determined from time of hospital admission to severe progression, based on clinical practice guidelines for COVID-19 in Japan.

resultsThe median value for HbA1c on admission was 6.1%, with diabetes present in 138 patients (33.3%). Among the total cohort, 93 (22.4%) progressed to severe COVID-19 with a median (interquartile range) time of 4 days (3-7 days), whereas 322 (77.6%) were discharged after 13 days (10-17 days). A multivariable Cox proportional hazards regression model showed that HbA1c level on admission was independently associated with progression to severe COVID-19 (hazard ratio for 1% increase 1.237, 95% confidence interval 1.037-1.475; P = 0.018), with findings consistent among several sensitivity analyses. In subgroup analyses, such an association was significant in patients with diabetes, as well as older age, current smoking habit, lower estimated glomerular filtration rate, higher C-reactive protein level, moderate II COVID-19, dyslipidemia and chronic respiratory disease, with no remarkable inconsistency among the subgroups. Finally, higher HbA1c level (≥7%) was more strongly associated with severe COVID-19 progression than diabetes.

conclusionsThe results suggest that poor glycemic control before COVID-19 onset contributes to progression from non-severe to severe COVID-19, even in patients with severe COVID-19 risk factors regardless of the presence of diabetes.

Indexed as

COVID-19Diabetes MellitusHyperglycemiaC-Reactive ProteinGlycated HemoglobinHumansRetrospective StudiesRisk FactorsC-Reactive ProteinGlycated HemoglobinCOVID-19Glycated hemoglobinSevere progression

Identifiers

PMID35616179
PMCPMC9348501
OpenAlexW4281552775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.